Research

ITQ

Worldwide Injection Technique Survey

This is the third Insulin Injection Technique survey to have taken place and is the largest and broadest yet, covering 41 countries worldwide with over 13000 questionnaires completed.

Specific objectives of this survey

• Understand the epidemiologic profiles for the major injection parameters
• Determine the major causes of variability in injection technique, their ranking and their interactions and
• Query the patients perception of the injection process, including the psychological, social and economic challenges

The results

• Results were analysed and discussed at FITTER congress
• The results influenced the drafting of our international Injection Technique, Safety and Infusion Recommendations
• The studies have been published in the Mayo Clinic Proceedings Journal. Click here and here to access the studies.

Download the FITTER ITQ Survey Injection Technique infographics

List of the Worldwide Injection Techniques Questionnaire (ITQ) - RESULTS:

• Lipohypertrophy
• Insulin Usage
• Descriptive Stats
• Needle Reuse
• Correct Site Rotation
• Needle Gauge
• Leakage from Site
• Injection Pain
• Education
• Glucose Instability
• Infusion ITQ Presentation

List of the Worldwide Injection Technique Questionnaire (ITQ) - FORMS (all languages):

• ITQ Questionnaire Nurse ARABIC
• ITQ Questionnaire Nurse CHINESE
• ITQ Questionnaire Nurse DANISH
• ITQ Questionnaire Nurse DUTCH
• ITQ Questionnaire Nurse GERMAN
• ITQ Questionnaire Nurse ITALIAN
• ITQ Questionnaire Nurse KOREAN
• ITQ Questionnaire Nurse PORTUGUESE
• ITQ Questionnaire Nurse SPANISH
• ITQ Questionnaire Nurse SWEDISH
• ITQ Questionnaire Nurse TURKISH
• ITQ Questionnaire Nurse ENGLISH
• ITQ Questionnaire Patients and Nurse FRENCH
• ITQ Questionnaire Patients ARABIC
• ITQ Questionnaire Patients CHINESE
• ITQ Questionnaire Patients DANISH
• ITQ Questionnaire Patients DUTCH
• ITQ Questionnaire Patients GERMAN
• ITQ Questionnaire Patients ITALIAN
• ITQ Questionnaire Patients KOREAN
• ITQ Questionnaire Patients PORTUGUESE
• ITQ Questionnaire Patients SPANISH
• ITQ Questionnaire Patients SWEDISH
• ITQ Questionnaire Patients TURKISH
• ITQ Questionnaire Patients ENGLISH

List of the Worldwide Injection Technique Questionnaire (ITQ) - STUDIES FOR PUBLICATION:

• Population Surveyed
• Injecting Practices
• Injecting Complications
• Education and the HCP
• Participating Centers and Countries

Infusion Survey

Multinational 'Insulin Infusion Set' Survey

A multinational survey was recently conducted on insulin pump users to investigate rates of metabolic and non-metabolic complications associated with infusion set use. The survey was distributed to patients and healthcare practitioners in the US, Canada, Germany, and France. In addition to the survey, healthcare practitioners also conducted a physical assessment of patients, as well as a review of their insulin pumps and patient charts. This data will help to reinforce the need to make infusion sets a greater part of the pump therapy discussion.

The findings of the survey were presented at FITTER by Phyllis Wolff, a leading diabetes expert with extensive experience working with patients who use insulin pumps.

Reviewed studies

List of references used to establish the new FITTER recommendations:

• Adams D, Elliott TSJ. A comparative user evaluation of three needle protective devices. Br J Nurs. 2003;12(8):470–474.
• Adams D, Elliott TSJ. Impact of safety needle devices on occupationally acquired needle stick injuries: a four-year prospective study. J Hosp Infect. 2006;64(1):50-55.
• Adams D. Safety-engineered needle devices: evaluation prior to introduction is essential. J Hosp Med. 2011;79(2):174-175.
• Ahern J, Mazur ML. Site rotation. Diabetes Forecast. 2001;54(4):66-68.
• Alexander H and Dugale A. Fascial planes with subcutaneous fat in humans. Eur J Clin Nutr. 1992;46(12): 903–906.
• American Association of Diabetes Educators. Insulin Pump Therapy: Best practices in choosing and using infusion devices. 2011.
• Ampudia-Blasco J, Girbes J, Carmena R. A case of lipoatrophy with insulin glargine. Diabetes Care. 2005;28(12):2983-2983.
• Anderson G, Meyer D, Herrman CE et al. Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study. J Neurol. 2010; 257(11):1917–1923.
• Annersten M, Frid A. Insulin pens dribble from the tip of the needle after injection. Pract Diab Int. 2000;17(4):109-111.
• Annersten M, Willman A. Performing subcutaneous injections: a literature review. Worldv Evid-Based Nu. 2005;2(3):122-130.
• Arendt-Nielsen L, Egekvist H, Bjerring P. Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res. 2006;23(1-2):37-43.
• Ariza-Andraca CR, Altamirano-Bustamante E, Frati-Munari AC, Altamirano-Bustamante P, Graef-Sanchez A. Delayed insulin absorption due to subcutaneous edema. Arch Invest Med. 1991;22(2):229-233.
• Aronson R, Gibney MA, Oza K, Bérubé J, Kassler-Taub K, Hirsch L. Insulin pen needles: effects of extra-thin wall needle technology on preference, confidence, and other patient ratings. Clin Ther. 2013 Jul;35(7):923-933.
• Aronson R. The role of comfort and discomfort in insulin therapy. Diabetes Technol Ther. 2012 Aug;14(8):741-7.
• Arranz A, Andia V, López-Guzmán A. A case of lipoatrophy with Lispro insulin without insulin pump therapy. Diabetes Care. 2004 Feb;27(2):625-6.
• Article 3.2 says that where risk cannot be eliminated the employer shall take appropriate measures to minimise the risks. Appropriate measures to minimise the risks would include the provision by employers of safer needle devices. (Cf. NHS Employers, Implementation advice on sharps agreement, 12th October 2010)
• Asakura T, Seino H, Kageyama M, Yohkoh N. Technical study of injection force of insulin injectors: at which angle to push the button. (in Japanese only) Progress in Medicine. 2009;29:1851-1856.
• Asakura T. A step to prevent blood in the cartridge of an insulin pen. (in Japanese only) Progress in Medicine. 2003;23(11):3066-3071.
• Asakura T. Comparison of clinically relevant technical attributes of five insulin injection pens. J Diab Sci Tech. 2011; 5(5):1203-1209.
• Association for Diabetescare Professionals (EADV). Guideline: The Administration of Insulin with the Insulin Pen. September 2008.
• Babiker A, Datta V. Lipoatrophy with insulin analogues in type I diabetes. Arch Dis Child. 2011 Jan;96(1):101-2.
• Bain A, Graham A. How do patients dispose of syringes? Pract Diab Int. 1998;15(1):19-21.
• Bantle JP, Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycaemia in type 1 diabetes subjects. Diabetes Care. 1993;16(12):1592-1597.
• Bantle JP, Weber MS, Rao SM, Chattopadhyay MK, Robertson RP. Rotation of the anatomic regions used for insulin injections and day-to-day variability of plasma glucose in type 1 diabetic subjects. JAMA. 1990;263(13):1802-1806.
• Baron AD, Kim D, Weyer C. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Curr Drug Targets. 2002;2(1):63-82.
• Bärtsch U, Comtesse C, Wetekam B. Insulin pens for treatment of diabetes (article in German). Ther Umsch. 2006;63(6):398-404.
• Becker D. Individualized insulin therapy in children and adolescents with type 1 diabetes. Acta Paediatr. 1998;87(Suppl 425):S20-S24.
• Belgium: Belgian Guidelines in Flemish: Nieuwe aanbevelingen voor injecties bij mensen met diabetes. Available from www.bddiabetes.be. Accessed 09 June 2016.
• Belgium: Belgian Guidelines in French: Nouvelles recommandations concernant les injections chez les personnes atteintes de diabète. Available from www.bddiabetes.be. Accessed 09 June 2016.
• Bergenstal RM, Strock ES, Peremislov D, et al. Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes. Mayo Clin Proc. 2015;90(3):329-338.
• Bienvenu OJ, Eaton WW. The epidemiology of blood-injection- injury phobia. Psychol Med. 1998;28(5):1129-36.
• Birkebaek NH, Solvig J, Hansen B, Jorgensen C, Smedegaard J, Christiansen JS. A 4-mm needle reduces the risk of intramuscular injections without increasing backflow to skin surface in lean diabetic children and adults. Diabetes Care. 2008 Sep;31(9):e65.
• Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013 Oct;39(5):445-53.
• Bohannon NJ. Insulin delivery using pen devices. Simple-to-use tools may help young and old alike. Postgrad Med. 1999;106(5):57-58.
• Bolick N. Performance qualification of a novel subcutaneous insulin infusion set using medical imaging. Diabetes. 2015;64(Suppl 1):A278. Presented 2015 at the American Diabetes Association annual meeting, Boston, USA.
• Bossi AC, Ansah EO. Bent needles: another problem in glycaemic control. Diabetes Care. 2008 Oct;31(10):e70. doi: 10.2337/dc08-0932
• Bossi AC, Veronesi G, Poerio CS, et.al. A prospective study for introducing insulin pens and safety needles in a hospital setting. The SANITHY (SAfety Needles and Insulin pens in Treviglio Hospital-ItalY) Study. CurDiab Reviews. 2016;12:1-8.
• Brady KA, Avner JR, Khine H. Perception and attitude of providers towards pain and anxiety associated with pediatric vaccine injection. Clinical Pediatrics. 2011;50(2):140-143.
• Breznik V, Kokol R, Luzar B, Miljković J. Insulin-induced localized lipoatrophy. Acta Dermatovenerol Alp Pannonica Adriat. 2013 Dec;22(4):83-5.
• Broadway CA. Prevention of insulin leakage after subcutaneous injection. Diabetes Educator. 1991;17(2):90-90.
• Brown A, Steel JM, Duncan C, Duncun A, McBain AM. An assessment of the adequacy of suspension of insulin in pen injectors. Diab Med. 2004;21(6):604-608.
• Burdick P, Cooper S, Horner B, Cobry E, McFann K, Chase HP. Use of a subcutaneous injection port to improve glycemic control in children with type 1 diabetes. Pediatr Diab. 2009;10(2):116-119.
• Byetta Pen User Manual. Eli Lilly and Company, 2007.
• Caffrey RM. Diabetes under control: Are all syringes created equal? Am J Nursing. 2003;103(6):46-49.
• Calara F, Taylor K, Han J, et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther. 2005;27(2):210-215.
• Catambing I, Villa M. Ultrasonographic Measurement of Skin and Subcutaneous Thickness at Insulin Injection Sites among Adult Filipinos with Diabetes. Journal of the ASEAN Federation of Endocrine Societies. 2014;29(1):24-32.
• Cefalu WT, Mathieu C, Davidson J, Freemantle N, Gough S, Canovatchel W. Patients' perceptions of subcutaneous insulin in the OPTIMIZE study: a multicenter follow-up study. Diab Tech Ther. 2008;10(1):25-38.
• Chantelau E, Lee DM, Hemmann DM, Zipfel U, Echterhoff S. What makes insulin injections painful? Brit Med J. 1991;303(6793):26-27.
• Chantelau E. Heinemann L, Ross D. Air Bubbles in insulin pens. Lancet. 1989;334(8659):387-388.
• China: Chinese Guidelines were published in 2011 in collaboration with the China Diabetes Society and are available at: http://www.diab.net.cn/guideline.jsp. Accessed 09 June 2016.
• Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. Brit Med J 2003;327(7411):383-384.
• Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. Brit Med J. 2003;327(7411):383-384.
• Cocoman A, Barron C. Administering subcutaneous injections to children: what does the evidence say? Journal Child Young People Nurs. 2008;2(2):84-89.
• Conwell LS, Pope E, Artiles AM, Mohanta A, Daneman A, Daneman D. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. J Pediatr. 2008;152(5):622-628.
• Conwell LS, Pope E, Artiles AM, Mohanta A, Daneman A, Daneman D. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents.  J Pediatrics. 2008;152(5): 622-628.
• Costigliola V, Frid A, Letondeur C, Strauss K. Needlestick injuries in European nurses in diabetes. Diabetes Metab. 2012;38 Suppl 1:S9-14.
• Council Directive 2010/32/EU, Official Journal of the European Union, L134/71 http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:134:0066:0072:EN:PDF. Accessed 09 June 2016.
• Cullen BL, Genasi F, Symington I, Bagg J, McCreaddie M, Taylor A, Henry M, Hutchinson SJ, Goldberg D. Potential for reported needle stick injury prevention among healthcare workers in NHS Scotland through safety device usage and improvement of guideline adherence: an expert panel assessment. J Hosp Infect. 2006;63(4): 445-451.
• Danish Nurses Organization. Evidence-based Clinical Guidelines for Injection of Insulin for Adults with Diabetes Mellitus. 2nd edition, December 2006.
• Davidson M. No need for the needle (at first). Diabetes Care. 2008;31(10):2070-2071.
• Davis ED, Chesnaky P. Site rotation..taking insulin. Diabetes Forecast. 1992;45(3):54-56.
• Davis SN, Renda SM. Psychological insulin resistance: overcoming barriers to starting insulin therapy. Diabetes Educator. 2006;32(Supp. 1):146S-152S.
• De Coninck C, Frid A, Gaspar R, et al. Results and analysis of the 2008-2009 Insulin Injection Technique Questionnaire survey.  J Diabetes. 2010;2(3):168-79. 
• de la Peña A, Ma X, Reddy S, Ovalle F, Bergenstal RM, Jackson JA. Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin. J Diabetes Sci Technol. 2014, 8(4):821-9.
• de la Peña A, Yeo KP, Linnebjerg H, et al. Subcutaneous injection depth does not affect the pharmacokinetics or glucodynamics of insulin lispro in normal weight or healthy obese subjects. J Diabetes Sci Technol. 2015;9(4):824-30.
• De Meijer PHEM, Lutterman JA, van Lier HJJ, van´t Laar A. The variability of the absorption of subcutaneously injected insulin; effect of injection technique and relation with brittleness. Diabetic Med. 1990;7(6):499-505.
• De Schryver A, Claesen B, Meheus A, van Sprundel M, François G. European survey of hepatitis B vaccination policies for healthcare workers. Eur J Public Health. 2011;21(3):338-43. Epublished at http://www.ncbi.nlm.nih.gov/pubmed?term=European%20survey%20of%20hepatitis%20B%20vaccination%20policies%20for%20healthcare%20workers. Accessed 09 June 2016.
• De Villiers FP. Lipohypertrophy - a complication of insulin injections. S Afr Med J. 2005;95(11):858-859.
• Definitions from Medline Plus, an online service of the US National Institutes of Health (NIH)
• Dejgaard A, Murmann C. Air bubbles in insulin pens. Lancet. 1989;334(8667):871.
• Del Olmo MI, Campos V, Abellán P, Merino-Torres JF, Piñón F. A case of lipoatrophy with insulin detemir. Diabetes Res Clin Pract. 2008 Apr;80(1):e20-1.
• Demir M, Serin E, Göktürk S, Ozturk NA, Kulaksizoglu S, Ylmaz U. The prevalence of occult hepatitis B virus infection in type 2 diabetes mellitus patients. Eur J Gastroenterol Hepatol. 2008 Jul;20(7):668- 73.
• Diamond S, Matok I. Pharmacists’ anticipated pain compared to experienced pain associated with insulin pen injection and fingertip. Can J Diab. 2011;35(3):282-286.
• DiMatteo RM, DiNicola DD, eds. Achieving patient compliance. The psychology of medical practitioner´s role. Oxford: Pergamon Press Inc. 1982, 233-256.
• Egekvist H, Bjerring P, Arendt-Nielson L. Pain and mechanical injury to human skin following needle insertions. Euro J Pain. 1999;3(1):41-49.
• Engström L, Jinnerot H, Jonasson E. Thickness of Subcutaneous Fat Tissue Where Pregnant Diabetics Inject Their Insulin - An Ultrasound Study. Poster at International Diabetes Federation, Mexico City, 2000.
• EU Commission for Employment, Social Affairs and Inclusion, New legislation to reduce injuries for 3.5 million healthcare workers in Europe, 8th March 2010.
• Famulla S, Hövelmann U, Fischer A, et al. Lipohypertrophy (LHT) leads to blunted, more variable insulin absorption and action in patients with type 1 diabetes (T1DM). Poster, American Diabetes Association annual meeting. Boston, 2015. Diabetes 2015;64(Suppl 1):A260-61.
• Famulla S, Hövelmann U, Fischer A, et al. Lipohypertrophy (LHT) leads to blunted, more variable insulin absorption and action in patients with type 1 diabetes (T1DM). Abstract at 2015 American Diabetes Association annual meeting in Boston, USA.
• Fernqvist-Forbes E, Linde B. Insulin absorption, glucose homeostasis, and lipolysis in IDDM during mental stress. Diabetes Care. 1991 Nov;14(11):1006-12.
• FIT web site containing most items produced by FIT: http://www.fit4diabetes.com/. Accessed 09 June 2016.
• Fitter4Diabetes website. http://www.fitter4diabetes.com. Accessed June 7, 2016.
• Fleming D, Jacober SJ, Vanderberg M, Fitzgerald JT, Grunberger G. The safety of injecting insulin through clothing. Diabetes Care. 1997;20(3):244-247.
• Franzen I, J. Ludvigsson. Specific instructions gave reduction of lipomas and improved metabolic control in diabetic children. Diabetologia. 1997;40, Supplement 1: A615 (1997).
• Frid A, Gunnarson R, Guntner P, Linde P. Effects of accidental intramuscular injection on insulin absorption in IDDM. Diabetes Care. 1988;11(1):41-45.
• Frid A, Hirsch L, Gaspar R, et al. New injection recommendations for patients with diabetes. Diabetes Metab. 2010;36(2):S3-S18.
• Frid A, Linde B. Intraregional differences in absorption of unmodified insulin from the abdominal wall. Diabet Med. 1992;9(3):236-239.
• Frid A, Linden B. Computed tomography of injection sites in patients with diabetes mellitus. Injection and Absorption of Insulin. Stockholm : Thesis, 1992.
• Frid A, Linden B. Clinically important differences in insulin absorption from the abdomen in IDDM. Diabetes Res Clin Pr. 1993;21(2):137-141.
• Frid A, Östman J, Linde B. Hypoglycemia risk during exercise after intramuscular injection of insulin in thigh in IDDM. Diabetes Care. 1990;13(5):473-477.
• Frid A. Fat thickness and insulin administration, what do we know? Infusystems Int. 2006;5(3):17-19.
• Fu A, Qiu Y, Radican L. Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes. Cur Med Res Opinion. 2009; 25(6):1413–1420.
• Fujikura J, Fujimoto M, Yasue S, et.al. Insulin-induced lipohypertrophy: report of a case with histopathology. Endocr J. 2005 Oct;52(5):623-8.
• Gasperoni C and Salgarello M. Liposuction related to the anatomy of subcutaneous fat and superficial fascial system. Aesthetic Plast Surg. 1995;19(1): 13–20.
• Genev NM, Flack JR, Hoskins PL, et al. Diabetes education; whose priorities are met? Diab Med. 1992;9(5):475-479.
• Gentile S, Agrusta M, Guarino G, et al. Metabolic consequences of incorrect insulin administration techniques in aging subjects with diabetes. Acta Diabetol. 2011;48(2):121-125. doi:10.1007/s00592-009-0172-x.
• Gibney M, Arce C, Byron K, Hirsch L. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin. 2010;26(6):1519-1530.
• Ginsberg BH. Parkes JL, Sparacino C. The kinetics of insulin administration by insulin pens. Horm Metab Research. 1994;26(12):584-587.
• Goebel-Fabbri AE, Fikkan J, Franko DL, et al. Insulin restriction and associated morbidity and mortality in women with type 1 diabetes. Diabetes Care. 2008;31(3):415-9.
• Goodpaster BH, Kelley DE, WingJohnson D, Cormack G, Abrahams P, and Dixon A. Computed tomographic observations on subcutaneous fat: implications for liposuction. Plast Reconstr Surg. 1996;97: 387–395.
• Gorman KC. Good hygiene versus alcohol swabs before insulin injections (Letter). Diabetes Care. 1993;16(6):960-961.
• Grassi G, Scuntero P, Trepiccioni R, et al. Optimizing insulin injection technique and its effect on blood glucose control. J Clin Translat Endo. 2014;1: 145-150. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). Accessed 09 June 2016.
• Guerci B, Sauvanet JP. Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab. 2005;31(4):4S7-4S24.
• Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006;129(1):174-81.
• Hambridge K. The management of lipohypertrophy in diabetes care. Br J Nurs. 2007;16(9):520-524.
• Hanas R, Adolfsson P, Elfvin-Akesson K, et al. Indwelling catheters used from the onset of diabetes decrease injection pain and pre-injection anxiety. J Pediatr. 2002;140(3):315-20.
• Hanas R, Ludvigsson J. Experience of pain from insulin injections and needle phobia in young patients with IDDM. Pract Diab Int. 1997;14(4):95-99.
• Hanas SR, Carlsson S, Frid A, Ludvigsson J. Unchanged insulin absorption after 4 days´use of subcutaneous indwelling catheters for insulin injections. Diabetes Care. 1997;20(4):487-490.
• Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes. 1996;104(1):106-110.
• Heinemann L, Hirsch L, Hovorka R. Lipohypertrophy and the artificial pancreas: is this an issue? J Diabetes Sci Technol, 2014 Sep;8(5):915-7. Published online 16 June 2014 at http://dst.sagepub.com/content/early/2014/06/16/1932296814538941 Accessed 09 June 2016.
• Heinemann L, Hompesch M, Kapitza C, Harvey NG, Ginsberg BH, Pettis RJ. Intra-dermal insulin lispro application with a new microneedle delivery system led to a substantially more rapid insulin absorption than subcutaneous injection. Diabetologia. 2006;49:755, abstract 1014.
• Heinemann L, Krinelke L. Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Technol. 2012;6(4):954-64.
• Heise T, Nosek L, Dellweg S, et.al. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. Diabetes Obes Metab. 2014 Oct;16(10):971-6.
• Henriksen JE, Djurhuus MS, Vaag A, et al. Impact of injection sites for soluble insulin on glycaemic control in type 1 (insulin-dependent) diabetic patients treated with a multiple insulin injection regimen. Diabetologia. 1993;36(8):752-758.
• Henriksen JE, Vaag A, Hansen IR, Lauritzen M, Djurhuus MS, Beck-Nielsen H. Absorption of NPH (isophane) insulin in resting diabetic patients; evidence for subcutaneous injection in the thigh as preferred site. Diabetic Medicine. 1991;8(5):453-457.
• Herdman M, Larck C, Hoppe Schliesser S, Jelic T. Biological contamination of insulin pens in a hospital setting. Am J Health Syst Pharm. 2013;70(14):1244-1248.
• Herdman ML, Larck C, Schliesser SH, Jelic TM. Biological contamination of insulin pens in a hospital setting.Am J Health Syst Pharm. 2013;70(14):1244-1248.
• Hildebrandt P. Skinfold thickness, local subcutaneous blood flow and insulin absorption in diabetic patients. Acta Physiol Scand. 1991;603:41-45.
• Hildebrandt P. Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influences of species, physico-chemical properties of insulin and physiological factors. Dan Med Bull. 1991;38(4):337-346.
• Hirose T, Ogihara T, Tozaka S, Kanderian S, Watada H. Identification and comparison of insulin pharmacokinetics injected with a new 4-mm needle vs 6- and 8-mm needles accounting for endogenous insulin and C-peptide secretion kinetics in non-diabetic adult males. J Diab Invest. 2013 May 6;4(3):287-96.
• Hirsch L, Byron K, Gibney M. Intramuscular risk at insulin injection sites-measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy. Diabetes Technol Ther. 2014;16(12):867-873.
• Hirsch L, Gibney M, Berube J, Manocchio J. The impact of a modified needle tip geometry on penetration force well as acceptability, preference and perceived pain in subjects with diabetes. J Diabetes Sci Technol. 2012, 1;6(2):328-35.
• Hirsch L, Ji L, Sun Z, Li Q, et al. Lipohypertrophy – Prevalence, risk factors and clinical characteristics of insulin-requiring patients in China. Diabetes Technol Ther. 2015;17(Suppl 1):A57-A58 
• Hirsch L, Klaff L, Bailey T, et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Curr Med Res Opin. 2010;26(6):1531-1541.
• Hirsch L, Klaff L, Bailey T, Gibney M, Albanese J, Qu S, Kassler-Taub K. Comparative glycemic control, safety and patient ratings for a new 4 mm\32G insulin pen needle in adults with diabetes Curr Med ResOpin 2010;26(6):1531–1541.
• Hirsch L. Continuous subcutaneous insulin infusion (CSII) sets: reduced flow interruptions with a novel catheter set. Diabetes. 2015;64(Suppl 1):A274-A275. Presented ADA 2015.
• Hirsch LJ, Gibney MA, Albanese J, et al. Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes. Curr Med Res Opin. 2010 Jun;26(6):1531-41.
• Hirsch LJ, Gibney MA, Li L, Bérubé J. Glycemic control, reported pain and leakage with a 4 mm × 32 G pen needle in obese and non-obese adults with diabetes: a post hoc analysis. Curr Med Res Opin. 2012 Aug;28(8):1305-11.
• Hirsch, Irl – personal communication, October 24, 2016.
• Hofman PL, Derraik JG, Pinto TE, et al. Defining the ideal injection techniques when using 5-mm needles in children and adults. Diabetes Care. 2010 Sep;33(9):1940-4.
• Hofman PL, Lawton SA, Peart JM, et al. An angled insertion technique using 6mm needles markedly reduces the risk of IM injections in children and adolescents. Diabet Med. 2007;24(12):1400-1405.
• Hofman PL, Lawton SA, Peart JM, et al. An angled insertion technique using 6-mm needles markedly reduces the risk of intramuscular injections in children and adolescents. Diabet Med. 2007 Dec;24(12):1400-5.
• Hofman, Paul. Personal Communication, October 24, 2015.
• Holstein A, Stege H, Kovacs P. Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature. Expert Opin Drug Saf. 2010 Mar;9(2):225-31.
• Hovelmann U, Famulla S, Hermanski L, et al. Insulin injection into regions with lipohypertrophy (LHT) worsens postprandial (PP) blood glucose (BG) versus injections into normal adipose tissue (NAT). Abstract at 2015 American Diabetes Association annual meeting in Boston, USA.
• Hovelmann U, Famulla S, Hermanski L, Fischer A, Heinemannn L, Kaltheuner M, Hirsch L, Heise T. Insulin injection into regions with lipohypertrophy (LHT) worsens postprandial (PP) blood glucose (BG) versus injections into normal adipose tissue (NAT). Poster, American Diabetes Association annual meeting. Boston, 2015. Diabetes 2015;64(Suppl 1):A254-55.
• http://handbook.cochrane.org/ Accessed 09 June 2016. See especially Chapter 8, ‘Assessing risk of bias in included studies’.
• http://www.internalmedicinenews.com/single-view/poll-hepatitis-b-vaccine-recommended-for-adults-with diabetes/7eff3bd28f.html Accessed 09 June 2016 and http://www.cdc.gov/vaccines/ Accessed 09 June 2016.
• Huzaira M, Rius F, Rajadhyaksha M, Anderson RR, González S. Topographic variations in normal skin, as viewed by in vivo reflectance confocal microscopy. J Invest Dermatol. 2001;116(6):846–852.
• Ignuat D, Fu H. Comparison of insulin diluent leakage postinjection using two different needle lengths and injection volumes in obese patients with type 1 or type 2 diabetes mellitus. J Diabetes Sci Technol. 2012;6(2): 389-393.
• India: Tandon N. l. Forum for Injection Technique (FIT), India: The Indian recommendations 2.0, for best practice in Insulin Injection Technique, 2015. Indian J Endocr Metab. 2015;19(3):317-331. This is the latest version of guidelines which were first published in India in 2012 and updated in 2013 and 2014.
• Italy: Italian Guidelines edited by Prof. Sandro Gentile: Consensus AMD-OSDI sulle Tecniche iniettive nel soggetto diabetic. A cura del Gruppo Inter-Societario AMD-OSDI sulle Tecniche iniettive. Il Giornale di AMD, 2014;17:176-181. http://www.giornalediamd.it/pdf/2014_3_F/8.pdf. Accessed 09 June 2016. Guidelines for correct injection technique and for prevention of lipodystrophy and the risk of accidental punctures. AMD-OSDI-SID Worksheet. Gentile S, Giancaterini A, Cucco L, Lograsso G, Porcellati F, Laviola L. Il Giornale di AMD, 2015; 18: 209-2017. http://www.aemmedi.it/files/Linee-guida_Raccomandazioni/2015/Documento_di_consenso_2015.pdf. Accessed 09 June 2016.
• Iwanaga M, Kamoi K. Patient perceptions of injection pain and anxiety: a comparison of NovoFine 32-gauge tip 6 mm and Micro Fine Plus 31-gauge 5 mm needles. Diabetes Technol Ther. 2009 Feb;11(2):81-6.
• Iwanaga M, Kamoi K. Patient perceptions of injection pain and anxiety: a comparison of NovoFine 32-gauge tip 6 mm and Micro Fine Plus 31-gauge 5 mm needles. Diabetes Technol Ther. 2009;11(2):81-86.
• Jagger J, Perry J, Gomaa A, Phillips EK. The impact of U.S. policies to protect healthcare workers from bloodborne pathogens: The critical role of safety-engineered devices. J Inf Pub Health. 2008;1(2):62-71.
• Jain SM, Pandey K, Lahoti A, Rao PK. Evaluation of skin and subcutaneous tissue thickness at insulin injection sites in Indian, insulin naïve, type-2 diabetic adult population. Indian J Endocrinol Metab. 2013;17(5):864-870.
• Jamal R, Ross SA, Parkes JL, Pardo S, Ginsberg BH. Role of injection technique in use of insulin pens: prospective evaluation of a 31-gauge, 8mm insulin pen needle. Endocr Pract. 1999;5(5):245-50.
• Jansà M, Colungo C, Vidal M. Actualización sobre técnicas y sistemas de administración de la insulina (II). Av Diabetol. 2008;24(4):255-269.
• Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet. 1999;354(9190):1604-1607.
• Jenkins N, Hallowell N, Farmer AJ, Holman RR, Lawton J. Initiating insulin as part of the Treating To Target in Type 2 Diabetes (4-T) trial: an interview study of patients' and health professionals' experiences. Diabetes Care. 2010 Oct;33(10):2178-80.
• Ji L, Li Q, Wei G. Lipohypertrophy - prevalence, risk factors and clinical characteristics of insulin-requiring patients in China. Abstract, EASD Vienna 2014, Tracking Number: A-14-747.
• Johansson U, Amsberg S, Hannerz L, et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care. 2005;28(8):2025-2027.
• Jorgensen JT, Romsing J, Rasmussen M, Moller-Sonnergaard J, Vang L, Musaeus L. Pain assessment of subcutaneous injections. Ann Pharmacother. 1996;30(7-8):729 -732.
• Joy SV. Clinical pearls and strategies to optimize patient outcomes. Diabetes Educator. 2008;34(3):S54-S59.
• Kahara T, Kawara S, Shimizu A, Hisada A, Noto Y, Kida H. Subcutaneous hematoma due to frequent insulin injections in a single site. Intern Med. 2004;43(2):148-149.
• Kaiser P, Maxeiner S, Weise A, Nolden F, Borck A, Forst T, Pfützner A. Assessment of the mixing efficiency of neutral protamine Hagedorn cartridges. J Diabetes Sci Technol. 2010 May 1;4(3):652-7.
• Kalra S, Girdhar R, Sahay R. Green diabetology. Ind J Endo Metab. 2015; 19(6): 698-700.
• Kalra S, Yashdeep Y. Clinical applications of intramuscular insulin. J EndoMetab. 2014;4(3):40-43.
• Karges B, Boehm BO, Karges W. Early hypoglycaemia after accidental intramuscular injection of insulin glargine. Diabetes Med. 2005;22(10):1444-1445.
• Karlegärd M, Eldholm S, Lindblad B, Sigström L. Stickrädsla hos barn och ungdomar med diabetes (Fear of injection in children and adolescents with diabetes). Sv Läkaresällskapets Handlingar Hygiea. 2001;110:301(32P).
• Karter AJ, Subramanian U, Saha C, Crosson JC, Parker MM, Swain BE, Moffet HH, Marrero DG. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010 Apr;33(4):733-5.
• Kawasaki E, Asakura T, Karasawa H, Yohkoh N. Examination of the Suspensibility of Insulin Suspensions in Clinical Use. (in Japanese only) J Japan Diab Soc. 2012;55(10):753-760.
• Kelley DE, Thaete FL, Troost F, Huwe T, Goodpaster BH. Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol Endocrinol Metab. 2000;278(5):E941-E948.
• King L. Subcutaneous insulin injection technique. Nurs Stand. 2003;17(34):45-52.
• Kiss P, de Meester M, Braeckman L. Needlestick injuries in nursing homes: the prominent role of insulin pens. Inf Control Hosp Epid. 2008;29(12):1192-1194.
• Klonoff DC. The pen is mightier than the needle (and syringe). Diab Tech Ther. 2001;3(4):631-633.
• Koivisto VA, Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med. 1980;92(1):59-61.
• Kølendorf K, Bojsen J, Deckert T. Clinical factors influencing the absorption of 125 I-NPH insulin in diabetic patients. Horm Metab Research. 1983;15(6):274-278.
• Kreugel G, Beijer HJM, Kerstens MN, ter Maaten JC, Sluiter WJ, Boot BS. Influence of needle size for SC insulin administration on metabolic control and patient acceptance. Europ Diab Nursing. 2007;4(2):1-5.
• Kreugel G, Keers JC, Jongbloed A, Verweij-Gjaltema AH, Wolffenbuttel BHR. The influence of needle length on glycemic control and patient preference in obese diabetic patients. Diabetes. 2009;58:A117.
• Kreugel G, Keers JC, Kerstens MN, Wolffenbuttel BH. Randomized trial on the influence of the length of two insulin pen needles on glycemic control and patient preference in obese patients with diabetes. Diabetes Technol Ther. 2011;13(7):737-741.
• Larkin ME, Capasso VA, Chen C, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educat. 2008; 34(3):511-17.
• Lasagni C, Seidenari S. Echographic assessment of age-dependent variations of skin thickness. Skin Res Technol. 1995;1:81-85.
• Laurent A, Mistretta F, Bottigioli D, et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine. 2007;25(34):6423-30.
• Le Floch JP, Herbreteau C, Lange F, Perlemuter L. Biologic material in needles and cartridges after insulin injection with a pen in diabetic patients. Diabetes Care. 1998;21(9):1502-1504.
• Lee DM. How painful is intensive insulin therapy? Z Gesamte Inn Med. 1992 Jun;47(6):266-9.
• Lee JM, Botteman MF, Nicklasson L, Cobden D, Pashos CL. Needlestick injury in acute care nurses caring for patients with diabetes mellitus: a retrospective study. Curr Med Res Opin. 2005;21(5):741-7.
• Lippert WC, Wall EJ. Optimal intramuscular needle-penetration depth. Pediatrics. 2008;122(3):e556-e563.
• Lo Presti D, Ingegnosi C, Strauss K. Skin and subcutaneous thickness at injecting sites in children with diabetes: ultrasound findings and recommendations for giving injection. Pediatr Diabetes. 2012;13(7):525-533.
• Louis N, Vela G, Groupe Projet. Évaluation de l’efficacité d’une mesure de prévention des accidents d’exposition au sang au cours du prèlévement de sang veineux. Bulletin Épidémiologique Hebdomadaire. 2002;51:260-261.
• Ludescher B, Rommel M, Willmer T, Fritsche A, Schick F, Machann J. Subcutaneous adipose tissue thickness in adults - correlation with BMI and recommendations for pen needle lengths for subcutaneous self-injection. Clin Endocrinol (Oxf). 2011;75(6):786-790.
• Lumber T. Tips for site rotation. When it comes to insulin. where you inject is just as important as how much and when. Diabetes Forecast. 2004;57(7):68-70.
• Maljaars C. Scherpe studie naalden voor eenmalig gebruik [Sharp study needles for single use] Diabetes and Levery. 2002;4:36-37.
• Markman B, and Barton JF. Anatomy of the subcutaneous tissue of the trunk and lower extremity. Plast Reconstr Surg. 1987;80(2): 248–254.
• Marran K, Segal D. SKINNY – Skin thickness and Needles in the Young. S Afr J CH. 2014;8(3):92-95 DOI:10.7196/SAJCH.687.
• Martinez L, Consoli SM, Monnier L, et al. Studying the Hurdles of Insulin Prescription (SHIP): development, scoring and initial validation of a new self-administered questionnaire. Health Qual Life Out. 2007;5(1):53-53.
• McCarthy JA, Covarrubias B, Sink P. Is the traditional alcohol wipe necessary before an insulin injection? Dogma disputed (Letter). Diabetes Care. 1993;16(1):402-402.
• McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients' perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. Diabetes Technol Ther. 2009;11(3):195-201.
• McVey E, Keith S, Herr JK, Sutter D, Pettis RJ. Evaluation of intradermal and subcutaneous infusion set performance under 24-hour basal and bolus conditions. J Diabetes Sci Technol. 2015 Aug 27;9(6):1282-91. doi: 10.1177/1932296815598327.
• Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educator. 2006;32(Supp. 1):9S-18S.
• Melissa K. Schaefer MK, Kossover RA, Perz JF. Sharing insulin pens: Are you putting patients at risk? Diabetes Care. 2013;36(11):e188-189.
• Meryl H. Mendelson, Bao Ying Lin-Chen, Lori Finkelstein-Blond, Eileen Bailey, Gene Kogan. Evaluation of a Safety IV Catheter (IVC) (Becton Dickinson, INSYTE™ AUTOGUARD™) : Final Report Eleventh Annual Scientific Meeting Society for Healthcare Epidemiology of America, 2001 SHEA, Toronto, Canada.
• Misnikova I, Dreval A, Gubkina V, Rusanova E.  The risk of repeated use of insulin pen needles in patients with diabetes mellitus.  J Diabetology. 2011, 1:1-5. 
• Miwa T, Itoh R, Kobayashi T, et al. Comparison of the effects of a new 32-gauge × 4-mm pen needle and a 32-gauge × 6-mm pen needle on glycemic control, safety, and patient ratings in Japanese adults with diabetes. Diab Tech Ther. 2012 Dec;14(12):1084-90.
• Mollema ED, Snoek FJ, Ader HJ, et al. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res. 2001;51(5):665-72.
• Mollema ED, Snoek FJ, Heine RJ. Assessment of perceived barriers in self-care of insulin-requiring diabetic patients. Patient Educ Counsel. 1996;29(3):277-81.
• Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, Yarasheski K. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis. 2007;44(5):726-34. Epub 2007 Jan 22.
• Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22(9):1501-1506.
• Mujika-Zabaleta A, Forbes A, While A, et al. Relationship between diabetes knowledge, glycaemic control and quality of life: Pilot study. Diab Prim Care. 2010;12:376-81.
• NACO (National AIDS Control Organization) guidelines from India. Accessible at http://www.naco.gov.in/NACO/. Accessed 8 June 2016.
• Nagai Y, Ohshige T, Arai K, Kobayashi H, Sada Y, Ohmori S. Comparison between shorter straight and thinner microtapered insulin injection needles. Diab Tech Ther. 2013;15(7):550-555.
• Nagase T, Iwaya K, Iwaki Y, et al. Insulin-derived amyloidosis and poor glycemic control: a case series. Amer J Med. 2014;127(5):450-454.
• Nagase T, Katsura Y, Iwaki Y, et al. The insulin ball. Lancet. 2009;373(9658):184-184.
• Nath C. Mixing insulin: shake, rattle or roll? Nursing. 2002;32(5):10.
• Nielsen BB, Musaeus L, Gæde P. Attention to injection technique is associated with a lower frequency of lipohypertrophy in insulin treated type 2 diabetic patients. Abstract European Association for the Study of Diabetes, Barcelona, Spain, 1998.
• Occupational Safety and Health Administration. Occupational exposure to bloodborne pathogens: needlesticks and other sharps injuries; finale rule. Federal Register. 2001; 66(12): 5317-5325.
• Okamura S, Hayashino Y, Kore-Eda S, Tsujii S. Localized Amyloidosis at the Site of Repeated Insulin Injection in a Patient With Type 2 Diabetes. Diabetes Care. 2013;36(12):e200-e200.
• Overland J, Molyneaux L, Tewari S, et al. Lipohypertrophy : Does it matter in daily life? A study using a continuous glucose monitoring system. Diab Obes Metab. 2009;11(5):460-463.
• Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care. 2000;23(6):813-819.
• Patel PJ, Benasi K, Ferrari G, et al. Randomized trial of infusion set function: steel versus teflon. Diabetes Technol Ther. 2014;16(1):15-9.
• Paton N. Why we must stop needlestick injuries. Nurs Times. 2006;102(40):16-8
• Pergallo-Dittko, V. Rethinking subcutaneous injection technique. Amer J Nursing. 1997, 97(5):71-72.
• Perriello G, Torlone E, Di Santo S, et al. Effect of storage temperature on pharmacokinetics and pharmadynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1988;31(11):811-815.
• Personal Communication: Anders Frid, October 24, 2015. Data on file: Novo Nordisk.
• Pettis RJ, Ginsberg B, Hirsch L, et al. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. Diab Tech Ther 2011;13(4):435-42. DOI 10.1089/ dia.2010.0184.
• Philippines: FIT-PHIL: Forum for Injection Technique Philippines. Available from BD, 11th Floor, Trade and Financial Tower, 7th Avenue corner 32nd Street, Bonifacio Global City, 1634 Taguig City , Philippines.
• Pickup J, Yemane N, Brackenridge A, Pender S. Nonmetabolic Complications of Continuous Subcutaneous Insulin Infusion: A Patient Survey. Diab Tech Therap. 2014; 16(3):145-9.
• Pickup JC, Keen H, Parsons JA, Alberti KG. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J. 1978;1(6107):204-207.
• Pickup, JC, Yemane N, Brackenridge A, Pender S. Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey. Diabetes Technol Ther. 2014;16(3): 145-149.
• Polak M, Beregszaszi M, Belarbi N, et al. Subcutaneous or intra-muscular injections of insulin in children: Are we injecting where we think we are? Diabetes Care. 1996;19(12):1434-1436.
• Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543-5.
• Polonsky WH, Jackson R. What’s so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diab. 2004;22(3):147-150.
• Puder J, Atar M, Muller B, Pavan M, Keller U.  Using insulin pen needles up to five times does not affect needle tip shape nor increase pain intensity.  Diab Res Clin Pract. 2005;67(2):119–123.
• Pugliese G, Germanson TP, Bartley J, Luca J, Lamerato L, Cox J, Jagger J. Evaluating sharps safety devices: Meeting OSHA’s intent. Infect Control Hosp Epidem. 2001; 22(7): 456-458.
• Qifu Li, Linong Ji, Zilin Sun, et al. Lipohypertrophy (LH) prevalence varies widely between Chinese cities - need for consistent LH diagnostic methods. Abstract at 2015 American Diabetes Association annual meeting in Boston, USA.
• Raile K, Noelle V, Landgraf R, Schwarz HP. Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diab. 2001;109(8):393–6.
• Rave K, Heise T, Weyer C, et. al. Intramuscular versus subcutaneous injection of soluble and lispro insulins: Comparison of metabolic effects in healthy subjects. Diabet Med. 1998;15(9):747-751.
• Reach G. Patient non-adherence and healthcare-provider inertia are clinical myopia. Diab Metab. 2008;34(4):382-385.
• Renard, E, Guerci B, Leguerrier AM, Boizel R; Accu-Chek FlexLink Study Group. Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-period, observational, multicenter study. Diabetes Technol Ther. 2010;12(10): 769-773.
• Rissler J, Jørgensen C, Rye Hansen M, Hansen NA. Evaluation of the injection force dynamics of a modified prefilled insulin pen. Expert Opin Pharmacother. 2008;9(13):2217-2222.
• Ross SA, Jamal R, Leiter LA, et al. Evaluation of 8 mm insulin pen needles in people with type 1 and type 2 diabetes. Pract Diab Int. 1999; 16(5):145-148.
• Ross SA, Jamal R, Leiter LA, et al. Evaluation of 8 mm insulin pen needles in people with type 1 and type 2 diabetes. Pract Diab Intl. 1999; 16(5):145-148.
• Rubin RR, Peyrot M, Kruger DF, Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ. 2009;35(6):1014-1022.
• Rubino A, McQuay LJ, Gough SC, et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med 2007;24(12):1412-8.
• Saez-de Ibarra L, Gallego F. Factors related to lipohypertrophy in insulin-treated diabetic patients; role of educational intervention. Pract Diab Intl. 1998;15(1):9-11.
• Schemes courtesy of Lourdes Saez-de Ibarra and Ruth Gaspar, Diabetes Nurses and Specialist Educators from La Paz Hospital, Madrid, Spain.
• Schmid V, Hohberg C, Borchert M, Forst T, Pfützner A. Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy—trouble starts on day 3. J Diabetes Sci Technol. 2010;4(4): 976-982.
• Schuler G, Pelz K, Kerp L. Is the reuse of needles for insulin injection systems associated with a higher risk of cutaneous complications? Diab Res Clin Pract. 1992;16(3):209-212.
• Schwartz S, Hassman D, Shelmet J, et al. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6mm needle versus a 29 gauge x 12.7mm needle in obese patients with diabetes mellitus. Clin Ther. 2004;26(10):1663-1678.
• Scioli D, Pizzella T, Vollaro L, Nardiello S, De Feo L: The action of VIRKON No Foam on the hepatitis B virus. Eur J Epidemiol. 1997;13(8):879–883.
• See ‘How do I decide where to inject?’ from Joslin Diabetes Center. http://www.joslin.org/info/how_to_improve_the_insulin_injection_experience.html. Accessed June 8, 2016.
• See ‘What is the best injection technique?’ from Joslin Diabetes Center. http://www.joslin.org/info/how_to_improve_the_insulin_injection_experience.html. Accessed June 8, 2016.
• Seyoum B, Abdulkadir J. Systematic inspection of insulin injection sites for local complications related to incorrect injection technique. Trop Doct. 1996;26(4):159-161.
• Shikata T, Karasawa T, Abe K, et al: Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis. 1977;136(4):571–576.
• Siegmund T, Blankenfeld H, Schumm-Draeger PM. Comparison of usability and patient preference for insulin pen needles produced with different production techniques: "thin-wall" needles compared to "regular-wall" needles: an open-label study. Diabetes Technol Ther. 2009 Aug;11(8):523-8.
• Significant portions of this section, as well as the Recommendations, have been lifted, with permission, from the WISE recommendations: Strauss K, WISE Consensus group. WISE recommendations to ensure the safety of injections in diabetes. Diabetes Metab. 2012;38 (Suppl 1):S2-8. doi: 10.1016/S1262-3636(12)70975-8.
• Sim KH, Hwang MS, Kim SY, Lee HM, Chang JY, Lee MK. The appropriateness of the length of insulin needles based on determination of skin and subcutaneous fat thickness in the abdomen and upper arm in patients with type 2 diabetes. Diabetes Metab J. 2014;38(2):120-133.
• Simó R, Hernández C, Genescà J, Jardí R, Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care. 1996 Sep;19(9):998-1000.
• Sindelka G, Heinemann L, Berger M, Frenck W, Chantelau E. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia. 1994;37(4):377-380.
• Solvig J, Christiansen JS, Hansen B, Lytzen L. Localisation of potential insulin deposition in normal weight and obese patients with diabetes using Novofine 6 mm and Novofine 12 mm needles. Abstract Federation European Nurses in Diabetes, Jerusalem, Israel, 2000.
• Sonoki K, Yoshinari M, Iwase M, Tashiro K, Iino K, Wakisaka M, Fujishima M. Regurgitation of blood into insulin cartridges in the pen-like injectors. Diabetes Care. 2001 Mar;24(3):603-4.
• Spraul M, Chantelau E, Koumoulidou J, Berger M. Subcutaneous or nonsubcutaneous injection of insulin. Diabetes Care. 1988;11(9):733-736.
• Springs MH. Shake, rattle, or roll?..”Challenging traditional insulin injection practices” Am J Nursing. 1999;99:14.
• Strauss K, De Gols H, Hannet I, Partanen TM, Frid A. A pan-European epidemiologic study of insulin injection technique in patients with diabetes. Pract Diab Int. 2002;19(3):71-76.
• Strauss K, De Gols H, Letondeur C, Matyjaszczyk M, Frid A. The second injection technique event (SITE), May 2000, Barcelona, Spain. Pract Diab Int. 2002;19(1):17-21.
• Strauss K, Hannet I, McGonigle J, et al. Ultra-short (5mm) insulin needles: trial results and clinical recommendations. Pract Diab Intl. 1999;16(7),218-221.
• Strauss K. Insulin injection techniques. Pract Diab Int. 1998;15:181-184
• Strauss K. Insulin injection techniques: Report from the 1st International Insulin Injection Technique Workshop, Strasbourg, France—June 1997. Pract Diab Int. 1998;15(6):16-20.
• Strauss, K., Hannet, I., McGonigle, J. et al. Ultra-short (5mm) insulin needles: trial results and clinical recommendations. Pract Diab Intl. 1999;16(5): 218–221.
• Sun Z, Li Q, Ji L, Qin G, et al. Lipohypertrophy: Prevalence, risk factors, clinical characteristics, and economic burden of insulin-requiring patients in China. Poster, EASD Stockholm, 2015. Diabetologia 2015;58(Suppl 1):S438-9.
• Swahn Å. Erfarenheter av 94000 osterilt givna insulininjektioner (Experiences from 94000 insulin injections given without skin swab). Sv Läkaresällskapets Handlingar Hygiea. 1982;92:160(3O).
• Swelheim HT, Westerlaken C, van Pinxteren-Nagler E, Bocca G. Lipoatrophy in a girl with type 1 diabetes: beneficial effects of treatment with a glucocorticoid added to an insulin analog. Diabetes Care. 2012 Mar;35(3):e22.
• Swift B, Hawkins PN, Richards C, Gregory R. Examination of insulin injection sites: an unexpected finding of localized amyloidosis. Diabetes UK. Diabetic Medicine. 2002;19(10):881-886.
• Swindle LD, Thomas SG, Freeman M, Delaney PM. View of Normal human skin in vivo as observed using fluorescent fiber-optic confocal microscopic imaging. J Invest Dermatol. 2003;121(4):706–712.
• Tan CY, Statham B, Marks R, Payne PA. Skin thickness measured by pulsed ultrasound: its reproducibility, validation and variability. Br J Dermatol. 1982;106(6):657-67.
• Tandon N, Kalra S, Balhara YS, et al. Forum for Injection Technique (FIT), India: The Indian recommendations 2.0, for best practice in Insulin Injection Technique, 2015. Indian J Endocr Metab. 2015;19(3):317-331.
• Tarantola A, Golliot F, Astagneau P, Fleury L, Brucker G, Bouvet E. CCLIN Paris-Nord blood and body fluids (BBF) exposure surveillance taskforce. Four-year surveillance from the northern France network. Am J Infect Control. 2003;31(6):357-63.
• Teft G. Lipohypertrophy: patient awareness and implications for practice. (Clinical Audit). J Diab Nursing. 2002;6(1):20-24.
• Ter Braak EW, Woodworth JR, Bianchi R, et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care. 1996;19(12):1437-1440.
• Thatcher G. Insulin injections. The case against random rotation. Am J Nursing. 1985;85(6):690-692.
• The Directive specifically requires: ‘eliminating the unnecessary use of sharps by implementing changes in practice and on the basis of the results of the risk assessment, providing medical devices incorporating safety-engineered protection mechanisms.’ Council Directive 2010/32/EU, Official Journal of the European Union, L134/71 and Council Directive 2010/32/EU, Official Journal of the European Union, L134/69.
• Thethi TK, Rao A, Kawji H, Mallik T, Yau CL, Christians U, Fonseca V. Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabetes Complications. 2010;24(2):73-8.
• Thomas DR, Fischer RG, Nicholas WC, Beghe C, Hatten KW, Thomas JN.  Disposable insulin syringe reuse and aseptic practices in diabetic patients. J Gen Intern Med. 1989;4(2):97-100.
• Thow J, Johnson A, Fulcher G, Home P. Different absorption of Isophane (NPH) Insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. Diabetic Medicine. 1990;7(3): 600-602.
• Thow J. Home P. Insulin Injection Technique. Brit Med J. 1990; 301(6742):3-4.
• Thow JC, Coulthard A, Home PD. Insulin injection site tissue depths and localization of a simulated insulin bolus using a novel air contrast ultrasonographic technique in insulin treated diabetic subjects. Diabetic Medicine. 1992;9(10):915-920.
• Thow JC, Home PD. Insulin injection technique: depth of injection is important. Brit Med J. 1990;301(6742):3-4.
• Torrance T. An unexpected hazard of insulin injection. Pract Diab Int. 2002;19(2):63-63.
• Tubiana-Rufi N, Belarbi N, Du Pasquier-Fediaevsky L, et al. Short needles (8 mm) reduce the risk of intramuscular injections in children with type 1 diabetes. Diabetes Care. 1999;22(10):1621-1625.
• Turkey: The Turkish guidelines edited by Prof. Dr. Ahmet Kaya are available at: http://www.bd.com/contentmanager/b_article.asp?Item_ID=27814&ContentType_ID=2&BusinessCode=20306&d=&s=tr&dTitle=Turkey&dc=tr&dcTitle=Turkey. Accessed 09 June 2016.
• Uzun S, lnanc N, Azal S. Determining optimal needle length for subcutaneous insulin injection. J Diab Nursing. 2001;5(10):83-87.
• Vaag A, Damgaard Pedersen K, Lauritzen M, Hildebrandt P, Beck-Nielsen H. Intramuscular versus subcutaneous injection of unmodified insulin; consequences for blood glucose control in patients with type 1 diabetes mellitus. Diabetic Med. 1990;7(4): 335-342.
• Vaag A, Handberg A, Laritzen M, et al. Variation in absorption of NPH insulin due to intramuscular injection. Diabetes Care. 1990;13(1):74-76.
• Vaag A, Handberg A, Lauritzen M, et al. Variation in absorption of NPH insulin due to intramuscular injection. Diabetes Care. 1990; 13(1): 74-76.
• van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther. 2011;13(6):607-14.
• Van Doorn LG, Alberda A, Lytzen L. Insulin leakage and pain perception with NovoFine 6 mm and NovoFine 12 mm needle lengths in patients with type 1 or type 2 diabetes. Diabetic Medicine. 1998;1:S50.
• Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007;77(2):231-6.
• Veronesi G, Poerio CS, Braus A, et.al. Insulin therapy in hospitalized patients with diabetes: determinants of nurse satisfaction using pen devices. The SANITHY (SAfety Needles and Insulin pens at Treviglio Hospital – ItalY) Study. Clin Diab Endo. 2015;15: 1-15. DOI 10.1186/s40842-015-0015-3
• Vidal M, Colungo C, Jansà M. Actualización sobre técnicas y sistemas de administración de la insulina (I). Av Diabetol. 2008;24(3):175-190.
• Vora JP, Peters JR, Burch A, Owens DR. Relationship between absorption of radiolabeled soluble insulin subcutaneous blood flow, and anthropometry. Diabetes Care. 1992;15(11):1484-1493.
• Vos D, Gotz HM, Richardus JH. Needlestick injury and accidental exposure to blood: The need for improving the hepatitis B vaccination grade among health care workers outside the hospital. Am J Infect Control. 2006;34(9):610-612.
• Wang W, Guo X, Shen G, et al. Skin and subcutaneous thickness at insulin injection sites in Chinese patients with diabetes: clinical implications. Diab Metab. 2016 In Press.
• Wittmann A, Köver J, Kralj N, et al. Insulin leakage value in relation to pen needle length and administered dose after subcutaneous injection. Diabetes Technol Ther. 2010 Aug;12(8):587-90.
• Workman RGN. Safe injection techniques. Prim Hlth C. 2000;10:43-50.
• World Health Organization. WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health-care settings. 2015
• Young RJ, Hannan WJ, Frier BM, et al. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care. 1984;7(5):479-480.
• Young RJ, Hannan WJ, Frier BM, Steel JM, Duncan LJ. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care. 1984;7(3):479-480.
• Zambanini A, Newson RB, Maisey M, et al. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract. 1999;46(3):239-46.
• Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diab Res Clin Pract. 1999;46(3):239-246.
• Zehrer C, Hansen R, Bantle J. Reducing blood glucose variability by use of abdominal insulin injection sites. Diabetes Educator. 1985;16(6):474-477.